OLON Group, a company that develops and produces active pharmaceutical ingredients (APIs) for contract development and manufacturing organizations (CDMO) and general markets, started construction of a new facility at its Rodano site in Milan, Italy. The facility will be entirely dedicated to managing and producing ultra-potent compounds, used for example as payloads and payload-linkers for antibody-drug conjugates (ADCs), one of the most promising emerging cancer therapies, which combines the...